Search for a trial

Improving diagnostics in pT1 colorectal cancer patients

The principal aim of this pilot study is to test whether ctDNA can be detected in peripheral blood of patients with an early CRC (i.e. pT1 CRC)

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU 285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Primary Objective:* The primary objective is to demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST),…

SURVive: investigating new imaging criteria for non-operative treatment following neoadjuvant chemoradiation in rectal cancer patients

Evaluation of the feasibility of the combination of (DW-)MRI and digital FDG-PET/CT for prediction of response to chemoradiation therapy.

Fluorescence Molecular Endoscopy of locally advanced esophageal carcinoma using bevacizumab-800CW to evaluate dose response after neoadjuvant chemoradiotherapy: a single-center feasibility study.

The primary objective of this study is to determine the safety and feasibility of fluorescence molecular endoscopy using the fluorescent tracer bevacizumab-800CW for identification of pathological complete response after neoadjuvant…

Autologous Dendritic Cells Loaded with Allogenic Tumor Lysate for Surgically Resected Pancreatic Cancer Patients (REACtiVe trial).

The aim of this research is to investigate whether it is feasible and safe to treat operated pancreatic cancer patients who have completed standard of care treatment with dendritic cell immunotherapy using dendritic cells loaded with autologous…

Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab (TARZAN-trial)

This study has been transitioned to CTIS with ID 2024-517119-59-00 check the CTIS register for the current data. *- To explore efficacy of neoadjuvant atezolizumab and bevacizumab following radiotherapy in low- to intermediate-risk rectal cancer• To…

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Primary• To evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first line treatment) as measured by Progression Free Survival (PFS) in subjects with Claudin (CLDN) 18.2-positive,…

A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma

Primary Objective:To determine whether the addition of eryaspase to chemotherapy improves overall survival (OS) in second-line treatment of pancreatic adenocarcinoma compared to chemotherapy alone.Secondary Objectives:• To compare progression-free…

RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE, EFFICACY, SAFETY AND TOLERABILITY OF EPA-FFA GASTRO-RESISTANT CAPSULES, IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)

Primary Objective* To determine the efficacy of EPA-FFA gastro-resistant capsules in patients with FAP in reducing polypectomy.Secondary Objectives* To evaluate the clinical disease progression.* To evaluate the long-term safety and tolerability of…

Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)

This study has been transitioned to CTIS with ID 2023-509287-26-00 check the CTIS register for the current data. To compare the progression free survival and neurotoxity of first line treatment with F-Nal-IRI, CapCar and CapOx.

The (cost)effectiveness of neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine based chemoradiotherapy and adjuvant gemcitabine for (borderline) resectable pancreatic cancer.

This study has been transitioned to CTIS with ID 2024-516260-29-00 check the CTIS register for the current data. To determine whether neoadjuvant FOLFIRINOX followed by surgery improves overall survival and quality of life compared to neoadjuvant…

APpendix derived PAncreatic cancer Reactive T-lymphocytes

To evaluate anti-tumor activity of T-cells in the GALT of patients with PDAC.

Multicentre, randomised controlled trial comparing TRansanal minimal InvAsive Surgery (TAMIS) and endoscopic Submucosal dIsseCtion (ESD) for resection of non-pedunculated rectal lesions.

The aim of this study is to compare both procedures with regard to recurrence rates and complete (R0) resection rate, and to put this into perspective against the costs and complication rates of both strategies and the burden perceived by patients…

External beam radiation therapy versus stent insertion for dysphagia relief in esophageal cancer: a multi-center randomized trial

Primary objectiveThe primary objective of this study is to compare the efficacy of EBRT versus SEMS insertion for palliation of malignant dysphagia in esophageal cancer patients at 4 weeks after start of treatment.Secondary objectivesSecondary…

Multicenter European prospective study on the efficacy and safety of the Focal C2 CryoBalloon Ablation System in patients with Barrett*s Esophagus-related neoplasia

To evaluate the efficacy and safety of the Focal C2 CryoBalloon* Ablation System (FCBAS) for the treatment of Barrett*s epithelium.

Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal cancer

To develop a model that predicts the probability of pathologic complete response to nCRT in esophageal cancer, by integrating diffusion weighted magnetic resonance imaging (DW-MRI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)…

The Diagnostic and Predictive Value of Different Biomarkers in Pancreatic Juice and Blood in Patients with Pancreatic Cancer.

To establish the diagnostic and predictive value of different biomarkers in patients with pancreatic cancer by the investigation of:- Mutated ct-DNA levels in pancreatic juice and blood.- Chromosomal instability in pancreatic juice and blood.- Pro-…

New biomarkers for prediction of response to FOLFIRINOX chemotherapy in pancreatic cancer patients.

To investigate whether there are differences in single nucleotide polymorphism*s (SNPs), circulating tumor DNA (ctDNA), micro RNA (miRNA) and immune profiles between responders and non-responders to FOLFIRINOX chemotherapy and between patients who…

Wide Area Transepithelial sample Esophageal Biopsy combined with Computer assisted 3-Dimensial Tissue Analysis (WATS) for the detection of High Grade Esophageal Dysplasia and Adenocarcinoma: A multicenter prospective, randomized, tandem study

To evaluate the utility of the WATS system, as a potential substitute for the random sampling method that is currently recommended as an adjunct to targeted biopsy

The effects of micellar curcumin (Espera) on the immune function of pancreatic cancer patients.

Determine whether micellar curcumin (Espera®) is able to improve the Systemic Immune Inflammation index in operable PDAC patients OR (metastasized) pancreatic cancer patients with stable disease after standard of care treatment.